| Literature DB >> 33359649 |
Xue-Tao Xu1, Jie Chen2, Xiang Ren2, Yu-Ran Ma2, Xiao Wang2, Yan-Yan Ma1, Den-Gao Zhao1, Ren-Ping Zhou3, Kun Zhang1, Susan Goodin4, Dong-Li Li1, Xi Zheng5.
Abstract
Cancer stem cell (CSC) plays an important role in pancreatic cancer pathogenesis and treatment failure. CSCs are characterized by their ability to form tumor spheres in serum-free medium and expression of CSC related markers. In the present study, we investigated the effect atorvastatin, celecoxib and tipifarnib in combination on proliferation and apoptosis in Panc-1 sphere-forming cells. The sphere-forming cells were isolated from Panc-1 cells by sphere-forming method. These sphere-forming cells showed CSC properties. The levels of CD44, CD133 and ALDH1A1 in the sphere-forming cells were increased. Moreover, Panc-1 sphere-forming cells were resistant to chemotherapeutic drug gemcitabine. Combined atorvastatin with celecoxib and tipifarnib synergistically decreased the sphere forming ability of Panc-1 cells and the drug combination also strongly inhibited cell proliferation and promoted apoptosis in the sphere-forming cells. The effects of the drug combination on the Panc-1 sphere-forming cells were associated with decreases in the levels of CD44, CD133 and ALDH1A1, and suppression of Akt and NF-κB activation. Results of the present study indicate that the combination of atorvastatin, celecoxib and tipifarnib may represent an effective approach for inhibiting pancreatic CSCs.Entities:
Keywords: Apoptosis; Atorvastatin; Celecoxib; Chemoresistant; Pancreatic cancer; Stem cells; Tipifarnib
Mesh:
Substances:
Year: 2020 PMID: 33359649 DOI: 10.1016/j.ejphar.2020.173840
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432